When adjusted to a multivariate COX risk model with known variables (age, MGMT methylation, IDH mutation, adjuvant chemotherapy cycle number, KPS score, and number of lobe involvement), our analysis showed that PFS was associated with MGMT methylation (HR:0.336, P:0.002), IDH mutation, number of adjuvant TMZ chemotherapy cycles (HR:0.224, P:< 0.01) and the number of tumor-involved lobes. Here, IDH1 is linked to neoplasm.